Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon (Q45786054)

16 December 2017

title

Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon (English)

1 reference

16 December 2017

1 reference

1 reference

1 reference

Lin CY

1

1 reference

16 December 2017

language of work or name

English

0 references

publication date

1 January 1995

1 reference

16 December 2017

published in

Kidney International

1 reference

16 December 2017

volume

47

1 reference

16 December 2017

issue

1

1 reference

16 December 2017

page(s)

225-230

1 reference

16 December 2017

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Association of human hepatocellular carcinoma and cirrhosis with hepatitis B virus surface and core antigens in the liver

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Hepatitis B virus-associated membraneous nephropathy: clinical features, immunological profiles and outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Hepatitis B virus deoxyribonucleic acid in kidney cells probably leading to viral pathogenesis among hepatitis B virus associated membranous nephropathy patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

The clinical course of hepatitis B virus-associated nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Membranous glomerulonephritis and hepatitis B surface antigen in children

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Hepatitis B surface antigen associated nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Improvement of proteinuria in a case of hepatitis B-associated glomerulonephritis after treatment with interferon

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Membranous nephropathy related to hepatitis B virus in adults

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two Chinese children

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Regulation of cytokine gene expression

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.27

7 January 2021

Identifiers

DOI

10.1038/KI.1995.27

1 reference

16 December 2017

Dimensions Publication ID

1029981110

0 references

1 reference

16 December 2017